CAR T therapy through a catheter for pediatric brain tumors
Part of Brain & nervous system, Cancer clinical trials.
This Phase 1 trial tests a personalized immune-cell treatment (CAR T) delivered directly in the brain-area space using a catheter. It may help children and young adults with hard-to-treat (recurrent or refractory) diffuse midline brain tumors like DIPG/DMG when standard options aren’t working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Ages 1 to 26 years
- You have DIPG/DMG at some point after standard treatment, or another brain/spinal cord cancer that has come back or won’t respond and has no standard option
- You can have cells collected (apheresis) or a previously made product is already available
- A CNS “reservoir” catheter (like an Ommaya or Rickham) is in place for delivery
- You’re expected to live at least 8 weeks and your strength/activity score is high enough (Lansky/Karnofsky ≥ 60)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR T cell therapy (BCB-276) for children and young adults with a type of brain tumor called DIPG. The therapy uses your own immune cells that are specially trained to attack the cancer.
This trial tests a new type of immunotherapy called B7H3 IL-7Ra CAR T-cells for children with DIPG, a tough-to-treat brain tumor. The treatment is given directly into the fluid around the brain using a special catheter, and the goal is to see if it's safe and if it can help fight the tumor.
This trial tests a new type of immunotherapy called CAR T cells—immune cells engineered in the lab to fight a specific brain tumor called ATRT (atypical teratoid rhabdoid tumor). The cells are designed to recognize and attack tumor cells that have a protein called GPC3, and are enhanced with immune-boosting signals to work better.
This Phase 1 study tests CAR T cells designed to target a marker called GD2 on brain tumors. It aims to see if the treatment is safe and whether it can shrink or control these tumors in children and young adults.
This trial tests a special immune-cell therapy (GD2 CAR T cells) made for pediatric brain tumor patients. It uses a planned treatment plan and monitoring to see if the therapy is safe and can work against the tumor.
This trial tests a new immune cell therapy (CAR T-cells) that targets a protein called CD70 found on some brain tumor cells. It is for children and young adults with newly diagnosed or recurrent high-grade glioma, including DIPG.
Hear when a new Central Nervous System Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.